Joint Development and Licensing of JTR-161, a Dental Pulp-Derived Stem Cell Product, with Teijin
First written in FY2018-Q1. 5 of 12 entries say "Restated". Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022SoftenedAnnual report
「For JTR-161/JR-161, a regenerative medicine product using allogeneic dental pulp-derived stem cells for acute-phase cerebral infarction that had been jointly developed with Teijin Limited, we agreed in April 2022 to terminate the joint development.」
The parties agreed to conclude joint development of JTR-161/JR-161 in April 2022, bringing activities under the joint development and licensing agreements toward an end. - FY2021-Q1RestatedAnnual report
「For the regenerative medicine product for the treatment of acute ischemic stroke using allogeneic dental pulp-derived stem cells (DPC), development code JTR-161/JR-161, we began a Phase I/II clinical trial in February 2019.」
The company reconfirmed that the Phase I/II clinical trial for JTR-161/JR-161 had begun under the joint development and licensing agreements with Teijin Limited. No transition to a new trial stage was reported. - FY2020-Q3RestatedAnnual report
「In the cell and regenerative medicine field, we entered into joint development and licensing agreements with Teijin Limited in July 2017 for a regenerative medicine product for the treatment of acute ischemic stroke using allogeneic dental pulp-derived stem cells (DPC), development code JTR-161/JR-161, and began administering the product to patients in a Phase I/II clinical trial in February of last year.」
The company reconfirmed that patient dosing had begun in the Phase I/II clinical trial under the joint development and licensing agreements for JTR-161/JR-161 with Teijin Limited. No transition to a new trial stage was reported. - FY2020-Q2AdvancedAnnual report
「In the cell and regenerative medicine field, we entered into joint development and licensing agreements with Teijin Limited in July of the year before last for a regenerative medicine product for the treatment of acute ischemic stroke using allogeneic dental pulp-derived stem cells (DPC), development code JTR-161/JR-161, and began administering the product to patients in a Phase I/II clinical trial in February of this year.」
JTR-161/JR-161 began patient dosing in a Phase I/II clinical trial under the joint development and licensing agreements with Teijin Limited. - FY2020-Q1RestatedAnnual report
「In the cell and regenerative medicine field, we entered into joint development and licensing agreements with Teijin Limited last July for a regenerative medicine product for the treatment of acute ischemic stroke using allogeneic dental pulp-derived stem cells (DPC), development code JTR-161, and began a Phase I/II clinical trial in October of last year.」
The company reconfirmed that the Phase I/II clinical trial was continuing under the joint development and licensing agreements for JTR-161 with Teijin Limited. - FY2019RestatedAnnual report
「For human dental pulp-derived stem cells (DPC), for which we established a production method using our proprietary technology, we entered into a joint development agreement with Teijin Limited in July 2017 for the treatment of acute ischemic stroke and began a Phase I/II trial in October of last year.」
The company reconfirmed that a Phase I/II trial had begun under the joint development and licensing agreements for JTR-161 with Teijin Limited. - FY2019-Q2AdvancedAnnual report
「In the cell and regenerative medicine field, we entered into a joint development agreement and a licence agreement with Teijin Limited last July for JTR-161, a regenerative medicine product using allogeneic dental pulp-derived stem cells (DPCs) for acute-phase cerebral infarction, and began a Phase I/II clinical trial in October this year.」
Following execution of the agreement with Teijin Limited, JTR-161 progressed to the stage of starting a Phase I/II clinical trial in October 2018. - FY2019-Q1RestatedAnnual report
「In the cell and regenerative medicine field, we entered into a joint development agreement and a licence agreement with Teijin Limited last July for JTR-161, a regenerative medicine product using allogeneic dental pulp-derived stem cells (DPCs) for acute-phase cerebral infarction, and are advancing research and development.」
The company reconfirmed that joint research and development of JTR-161 was under way following execution of the agreement with Teijin Limited. No progression to a new clinical trial stage was reported. - FY2018AdvancedAnnual report
「For human dental pulp-derived stem cells (DPC), for which we established a production method using our proprietary technology as a regenerative medicine product following Temcell® HS Injection, we entered into a joint development agreement with Teijin Limited last July for the treatment of acute ischemic stroke. The two companies will work together to advance development toward starting clinical trials during fiscal 2018, with the aim of developing the product as a core next-generation regenerative medicine product.」
Following the joint development and licensing agreements for JTR-161 with Teijin Limited, development advanced toward starting clinical trials during fiscal 2018. The R&D pipeline states that preparations are under way for a Phase I/II clinical trial. - FY2018-Q3AdvancedAnnual report
「In the cell and regenerative medicine field, we entered into a joint development agreement and a licence agreement with Teijin Limited in July last year for JTR-161, a regenerative medicine product using allogeneic dental pulp-derived stem cells (DPCs) for acute-phase cerebral infarction, and are jointly advancing its development.」
The company stated that it was advancing joint development of JTR-161 following the execution of the joint development and licensing agreements with Teijin Limited. - FY2018-Q2AchievedAnnual report
「On 18 July of this year, we entered into joint development and licensing agreements with Teijin Limited for a regenerative medicine product.」
The joint development and licensing agreements for JTR-161, which were under negotiation in the previous quarter, were completed on 18 July 2017. - FY2018-Q1First statedAnnual report
「In addition, as part of our licensing business, we continued negotiations with Teijin Limited to enter into a joint development agreement and a licensing agreement for a regenerative medicine product for the treatment of acute ischemic stroke using allogeneic dental pulp-derived stem cells (DPC), development code JTR-161. (Note) On 18 July of this year, we entered into a joint development agreement for human dental pulp-derived stem cells.」
Negotiations progressed with Teijin Limited for joint development and licensing agreements for JTR-161. The filing states that a joint development agreement for human dental pulp-derived stem cells was entered into on 18 July 2017.